ClinicalTrials.gg
CompletedNCT00724126TARGET 2Updated Nov 29, 2019Results posted

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

A Phase 3 interventional study of Rifaximin and Placebo in Non-Constipation Irritable Bowel Syndrome, sponsored by Bausch Health Americas, Inc.. Completed at 88 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-29.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
637
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing rifaximin in Diarrhea — 1 open to participants now, 2 under way, none of them phase 3. Rifaximin · Diarrhea.

Enrollment
4th of 19
637 · median 210
Started
2008
with 1 other
Phase 3
10 of 19
none open now
Registered
7th of 19
by date
Lead sponsor
7 of 19
Bausch Health Americas, Inc.

Among the 19 studies testing rifaximin in Diarrhea, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 10 in phase 3, and was the 7th registered.

Diarrhea

879 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

Browse Diarrhea studies →

Open to participants now

1 of the 19 studies testing rifaximin in Diarrhea is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About rifaximin

Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing rifaximin in Diarrhea, or all of them as a file.
02

Study summary

To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.

03

Conditions studied

  • Non-Constipation Irritable Bowel Syndrome

Keywords

  • Diarrhea
  • Rifaximin
  • IBS
  • Abdominal pain
  • Bloating
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed IBS diagnosis per Rome II criteria for diagnosis of IBS.
  • Colonoscopy within 2 years as part of IBS diagnostic evaluation.
  • Has active symptoms of non-constipation IBS at baseline as measured by average daily scores for abdominal pain/discomfort, bloating, and stool consistency.

Exclusion criteria

Exclusion Criteria:

  • Symptoms of constipation.
  • History of other gastrointestinal diseases.
  • Type 1 or 2 diabetes.
  • Lactose intolerance not controlled by lactose-free diet.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
637 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.

    Drug: Placebo

  • Experimental
    Rifaximin

    Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.

    Drug: Rifaximin

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).

    The primary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of global IBS symptoms was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? \[Yes/No\]"

    Time frame: 4 weeks

Secondary outcomes

  1. Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6)

    The secondary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of bloating was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to your symptom of bloating, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptom of bloating? \[Yes/No\]."

    Time frame: 4 weeks

07

Results

Posted Jul 28, 2014

Participant flow

Participant flow — Overall Study
MilestonePlaceboRifaximin
Started321316
Completed302301
Not completed1915
Withdrew: Adverse event20
Withdrew: Withdrawal by subject86
Withdrew: Lost to follow-up66
Withdrew: Noncompliance21
Withdrew: Subject randomized although ineligible11
Withdrew: Subject had to leave vicinity of site01

Outcome measures

PrimaryProportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).

The primary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of global IBS symptoms was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? \[Yes/No\]"

Time frame:
4 weeks
Reported as:
Number · percentage of responders
Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).
percentage of respondersPlaceboRifaximin
Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).32.240.6
Statistical analysis
  • Placebo vs Rifaximin · Regression, Logistic · p = 0.03The p-value was obtained from a logistic regression model with fixed effects for treatment arm and analysis center.
SecondaryProportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6)

The secondary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of bloating was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to your symptom of bloating, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptom of bloating? \[Yes/No\]."

Time frame:
4 weeks
Reported as:
Number · percentage of responders
Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6)
percentage of respondersPlaceboRifaximin
Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6)31.941.0
Statistical analysis
  • Placebo vs Rifaximin · Regression, Logistic · p = 0.02The p-value was obtained from a logistic regression model with fixed effects for treatment arm and analysis center.

Adverse events

Collected over 12 weeks. Adverse events were collected during the 2-week treatment period and during the 10-week follow-up period.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—7/320 (2.2%)94/320 (29.4%)
Rifaximin—7/315 (2.2%)86/315 (27.3%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlaceboRifaximin
Chest painGeneral disorders2/3201/315
MeningitisInfections and infestations0/3201/315
Atrial fibrillationCardiac disorders0/3201/315
Non-cardiac chest painGeneral disorders0/3201/315
Intervertebral disc displacementMusculoskeletal and connective tissue disorders0/3201/315
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3201/315
HypoaesthesiaNervous system disorders0/3201/315
HypertensionVascular disorders0/3201/315
AppendicitisInfections and infestations1/3200/315
Metabolic acidosisMetabolism and nutrition disorders1/3200/315
Most frequent other events
Most frequent other events
EventPlaceboRifaximin
Upper respiratory tract infectionInfections and infestations30/32027/315
HeadacheNervous system disorders26/32020/315
NasopharyngitisInfections and infestations16/32012/315
DiarrhoeaGastrointestinal disorders7/32013/315
Abdominal painGastrointestinal disorders11/32010/315
NauseaGastrointestinal disorders11/3205/315
SinusitisInfections and infestations4/32010/315
BronchitisInfections and infestations9/3207/315
ConstipationGastrointestinal disorders8/3201/315
Back painMusculoskeletal and connective tissue disorders8/3207/315

Baseline characteristics

The analysis population was the intent-to-treat population, defined as subjects who received at least 1 dose of study drug. Two randomized subjects (1 in each group) did not receive study drug and were not included in the intent-to-treat population.

Age, Categorical
Age, Categorical(Participants)PlaceboRifaximinTotal
<=18 years101
Between 18 and 65 years282285567
>=65 years373067
Age, Continuous
Age, Continuous(years)PlaceboRifaximinTotal
Mean46.3 ± 14.645.9 ± 13.946.1 ± 14.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRifaximinTotal
Female225227452
Male9588183
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboRifaximinTotal
American Indian or Alaska Native213
Asian268
Native Hawaiian or Other Pacific Islander033
Black or African American142135
White302282584
More than one race022
Unknown or Not Reported000
08

Study locations

88 sites
  • Anniston, Alabama 36207, United States
  • Birmingham, Alabama 35205, United States
  • Huntsville, Alabama 35801, United States
  • Tempe, Arizona 85282, United States
  • Anaheim, California 92801, United States
  • Carmichael, California 95608, United States
  • Chula Vista, California 91910, United States
  • Concord, California 94520, United States
  • Garden Grove, California 92840, United States
  • Laguna Hills, California 92653, United States
  • Lakewood, California 90712, United States
  • Los Angeles, California 90048, United States
  • Monterey, California 93940, United States
  • Orange, California 92868, United States
  • Roseville, California 95661, United States
  • San Carlos, California 94070, United States
  • San Francisco, California 94117, United States
  • Bristol, Connecticut 06010, United States
  • Hamden, Connecticut 06518, United States
  • Newark, Delaware 19713, United States
  • Boca Raton, Florida 33486, United States
  • Hollywood, Florida 33021, United States
  • Largo, Florida 33777, United States
  • New Port Richey, Florida 34655, United States
  • New Smyrna Beach, Florida 32168, United States
  • Port Orange, Florida 32127, United States
  • Saint Petersburg, Florida 33709, United States
  • Tampa, Florida 33607, United States
  • Zephyrhills, Florida 33542, United States
  • Atlanta, Georgia 30342, United States
  • Macon, Georgia 31201, United States
  • Elkhart, Indiana 46514, United States
  • Kansas City, Kansas 66160, United States
  • Topeka, Kansas 66606, United States
  • Bowling Green, Kentucky 42104, United States
  • Metairie, Louisiana 70006, United States
  • Monroe, Louisiana 71201, United States
  • Baltimore, Maryland 21229, United States
  • Elkridge, Maryland 21075, United States
  • Wellesley, Massachusetts 02481, United States
  • Ann Arbor, Michigan 48109, United States
  • Troy, Michigan 48098, United States
  • Wyoming, Michigan 49519, United States
  • Mexico, Missouri 65265, United States
  • Sicklerville, New Jersey 08081, United States
  • Voorhees, New Jersey 08043, United States
  • Albuquerque, New Mexico 87102, United States
  • Great Neck, New York 11021, United States
  • Mineola, New York 11501, United States
  • New York, New York 10016, United States
  • North Massapequa, New York 11758, United States
  • Pomona, New York 10970, United States
  • Stony Brook, New York 11790, United States
  • Boone, North Carolina 28607, United States
  • Chapel Hill, North Carolina 27514, United States
  • Charlotte, North Carolina 28209, United States
  • Greensboro, North Carolina 27403, United States
  • Greensboro, North Carolina 27408, United States
  • New Bern, North Carolina 28562, United States
  • Wilmington, North Carolina 28401, United States
  • Winston-Salem, North Carolina 27103, United States
  • Canton, Ohio 44718, United States
  • Cincinnati, Ohio 45242, United States
  • Dayton, Ohio 45415, United States
  • Downingtown, Pennsylvania 19335, United States
  • Newtown, Pennsylvania 18940, United States
  • Pittsburgh, Pennsylvania 15206, United States
  • Sayre, Pennsylvania 18840, United States
  • Anderson, South Carolina 29621, United States
  • Columbia, South Carolina 29203, United States
  • Bristol, Tennessee 37620, United States
  • Chattanooga, Tennessee 37421, United States
  • Franklin, Tennessee 37067, United States
  • Germantown, Tennessee 38138, United States
  • Jackson, Tennessee 38301, United States
  • Kingsport, Tennessee 37660, United States
  • El Paso, Texas 79902, United States
  • Houston, Texas 77024, United States
  • Lewisville, Texas 75057, United States
  • Plano, Texas 75075, United States
  • San Antonio, Texas 78229, United States
  • Salt Lake City, Utah 84107, United States
  • Burlington, Vermont 05401, United States
  • Chesapeake, Virginia 23320, United States
  • Fairfax, Virginia 22031, United States
  • Spokane, Washington 99208, United States
  • Milwaukee, Wisconsin 53215, United States
  • Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409. PubMed 21208106 ↗
  • Schoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, Paterson C, Bortey E, Forbes WP. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014 May;39(10):1161-8. doi: 10.1111/apt.12735. Epub 2014 Apr 3. PubMed 24697851 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Aug 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2008
First posted
Jul 29, 2008
Start
Jul 2008
Primary completionActual
Aug 2009
CompletionActual
Sep 2009
Results first posted
Jul 28, 2014
Last update
Nov 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00724126
Responsible party
Sponsor
First posted
Jul 29, 2008
Start date
Jul 2008
Primary completion
Aug 2009
Completion
Sep 2009
Results posted
Jul 28, 2014
Last update
Nov 29, 2019

Study contacts

Enoch Bortey
study director · Bausch Health Americas, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion